Looking to the future, while the role of STAT3 has been established in cancer biology, identifying tumor biomarkers that can indicate patient sensitivity to STAT3 inhibition and expansion of target inhibition to other aberrant transcription factors will be important. The gene discussed is STAT3; the disease is neoplasm.